share_log

Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8

Benzinga ·  Mar 21, 2023 09:05

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment